Frederick L. Locke

31.9k total citations · 3 hit papers
307 papers, 6.0k citations indexed

About

Frederick L. Locke is a scholar working on Oncology, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, Frederick L. Locke has authored 307 papers receiving a total of 6.0k indexed citations (citations by other indexed papers that have themselves been cited), including 259 papers in Oncology, 90 papers in Immunology and 69 papers in Pathology and Forensic Medicine. Recurrent topics in Frederick L. Locke's work include CAR-T cell therapy research (245 papers), Lymphoma Diagnosis and Treatment (68 papers) and Biosimilars and Bioanalytical Methods (53 papers). Frederick L. Locke is often cited by papers focused on CAR-T cell therapy research (245 papers), Lymphoma Diagnosis and Treatment (68 papers) and Biosimilars and Bioanalytical Methods (53 papers). Frederick L. Locke collaborates with scholars based in United States, France and Germany. Frederick L. Locke's co-authors include Sattva S. Neelapu, Yi Lin, Jason R. Westin, Partow Kebriaei, Sherry Adkins, Sudhakar Tummala, William G. Wierda, Nitin Jain, Patrick Hwu and Alison Gulbis and has published in prestigious journals such as Circulation, Nature Medicine and The Journal of Experimental Medicine.

In The Last Decade

Frederick L. Locke

274 papers receiving 5.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

2017 1.6k citations Sattva S. Neelapu, Partow Kebriaei et al. profile →
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

2017 463 citations Frederick L. Locke, Sattva S. Neelapu et al. profile →
Unanswered questions following reports of secondary malignancies after CAR-T cell therapy

2024 132 citations Marcelo C. Pasquini, Frederick L. Locke et al. profile →

Peers

Countries citing papers authored by Frederick L. Locke

Since Specialization

Citations

This map shows the geographic impact of Frederick L. Locke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frederick L. Locke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frederick L. Locke more than expected).

Fields of papers citing papers by Frederick L. Locke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frederick L. Locke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frederick L. Locke. The network helps show where Frederick L. Locke may publish in the future.

Co-authorship network of co-authors of Frederick L. Locke

This figure shows the co-authorship network connecting the top 25 collaborators of Frederick L. Locke. A scholar is included among the top collaborators of Frederick L. Locke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frederick L. Locke. Frederick L. Locke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Humanin-like 8 regulates metabolic fitness and anti-apoptotic programming in CD19 CAR-T cells 2025 ·Blood ·Samira Naderinezhad, (unknown), (unknown), Bin Fang, Meghan Menges, John M. Koomen, (unknown), Frederick L. Locke	0
2	Plain language summary of the ZUMA-7 study of axicabtagene ciloleucel versus standard of care for people with relapsed or refractory large B-cell lymphoma 2025 ·Future Oncology ·Frederick L. Locke, Jason R. Westin, Christina To	0
3	Awakening from REMS: ASTCT 80/20 Ongoing Recommendations for Safe Use of Chimeric Antigen Receptor T Cells 2025 ·Transplantation and Cellular Therapy ·Frederick L. Locke, Zahra Mahmoudjafari, Partow Kebriaei, Rebecca Gardner, Matthew J. Frigault, Noelle V. Frey, Krishna V. Komanduri, Miguel‐Angel Perales, Sarah Nikiforow	3
4	Tocilizumab Prophylaxis Following Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma 2024 ·Transplantation and Cellular Therapy ·Frederick L. Locke, Sattva S. Neelapu, Nancy L. Bartlett, Lazaros J. Lekakis, Caron A. Jacobson, Ira Braunschweig, Olalekan O. Oluwole, Tanya Siddiqi, Yi Lin, John M. Timmerman, Marie José Kersten, (unknown), (unknown), (unknown), Rhine R. Shen, Harry Miao, Jenny Kim, David B. Miklos	13
5	Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7 2024 ·Blood Advances ·Armin Ghobadi, Javier Muñoz, Jason R. Westin, Frederick L. Locke, David B. Miklos, Aaron P. Rapoport, Miguel‐Angel Perales, Patrick M. Reagan, Joseph P. McGuirk, Caron A. Jacobson, Marie José Kersten, Irit Avivi, (unknown), Marco Schupp, Christina To, Olalekan O. Oluwole	4
6	Radiomic features of PET/CT imaging of large B cell lymphoma lesions predicts CAR T cell therapy efficacy 2024 ·Frontiers in Oncology ·Yoganand Balagurunathan, (unknown), Jin Qi, Zachary Thompson, Erin Dean, Hong Lü, Saran Vardhanabhuti, (unknown), Jung Woo Choi, Jenny Kim, Mike Mattie, Michael D. Jain, Frederick L. Locke	2
7	Real-World Trends of Cytokine Release Syndrome and Neurologic Events, and Pattern of Their Management Among Patients Receiving Axicabtagene Ciloleucel for Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) in the US: A CIBMTR Report 2024 ·Blood ·(unknown), Shakthi Bhaskar, Babatunde Adedokun, Olalekan O. Oluwole, Leland Metheny, Amy Moskop, Caron A. Jacobson, Geoffrey Shouse, Sairah Ahmed, Armin Ghobadi, Saurabh Dahiya, Jiali Yan, Zhen‐Huan Hu, Timothy Best, Jenny Kim, (unknown), Marcelo C. Pasquini, Frederick L. Locke	2
8	Cohort Comparison of Therapy-Related Myeloid Neoplasms after CAR T-Cell Therapy, Autologous Stem Cell Transplant, and Standard Cancer Therapies 2024 ·Blood ·Juan Manuel Mancilla Díaz, Saurabh Dahiya, (unknown), Maeve O’Reilly, Kai Rejeski, Veit Buecklein, Marion Subklewe, Gloria Iacoboni, Pere Barba, Claire Roddie, Frederick L. Locke, Jay Y. Spiegel, Najla H. Al Ali, (unknown), Jongphil Kim, Rami S. Komrokji, Michael D. Jain	0
9	Repeatability of metabolic tumor burden and lesion glycolysis between clinical readers 2023 ·Frontiers in Immunology ·Jung Woo Choi, Erin Dean, Hong Lu, Zachary Thompson, Qi Jin, (unknown), Michael D. Jain, Frederick L. Locke, Yoganand Balagurunathan	5
10	838P Matching-adjusted indirect comparison (MAIC) of axicabtagene ciloleucel (axi-cel) and epcoritamab (epcor) in relapsed/refractory (R/R) large B cell lymphoma (LBCL) after at least two prior systemic therapies (3L+) 2023 ·Annals of Oncology ·Olalekan O. Oluwole, M. D. Ray, (unknown), Keith Chan, Isabella Zhang, (unknown), Harvey E. Smith, (unknown), Anik R. Patel, Frederick L. Locke	3
11	Modulating the polyamine/hypusine axis controls generation of CD8+ tissue-resident memory T cells 2023 ·JCI Insight ·(unknown), (unknown), Mario R. Fernandez, Chunying Yang, Lancia Darville, (unknown), John M. Koomen, Otto Phanstiel, (unknown), John E. Mullinax, Shari Pilon‐Thomas, Frederick L. Locke, Pearlie K. Epling‐Burnette, John L. Cleveland	15
12	Paired Analysis from Patients with Myeloma Elucidates Favorable CAR-T Manufacture and Phenotype, Starting from Mobilized Pre-Transplant Apheresis Vs. Non-Mobilized Apheresis after Four Prior Lines 2023 ·Blood ·Ciara L. Freeman, (unknown), Meghan Menges, (unknown), Hien Liu, (unknown), (unknown), (unknown), (unknown), (unknown), José L. Ochoa-Bayona, Rachid Baz, Doris K. Hansen, Melissa Alsina, Kenneth H. Shain, Taiga Nishihori, (unknown), Frederick L. Locke	1
13	Applying the Novel EHA/EBMT Grading System for Icaht Following CAR-T Therapy: Comparative Incidence across Disease Entities and Association with Infections and Mortality 2023 ·Blood ·Kai Rejeski, Doris K. Hansen, Yucai Wang, Gloria Iacoboni, Emmanuel Bachy, Radhika Bansal, Olaf Penack, (unknown), Wolfgang Bethge, Javier Muñoz, Razan Mohty, Veit Buecklein, Pere Barba, Frederick L. Locke, Yi Lin, Michael D. Jain, Marion Subklewe	1
14	Mechanisms of Resistance to Chimeric Antigen Receptor T Cell Therapy 2023 ·Hematology/Oncology Clinics of North America ·(unknown), Frederick L. Locke	2
15	The CAR‐HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL 2023 ·American Journal of Hematology ·Kai Rejeski, Yucai Wang, Omar Albanyan, Javier Muñoz, Pierre Sesques, Gloria Iacoboni, Lucía López‐Corral, (unknown), Veit Bücklein, Razan Mohty, Martin Dreyling, Aliyah Baluch, Bijal Shah, Frederick L. Locke, Georg Heß, Pere Barba, Emmanuel Bachy, Yi Lin, Marion Subklewe, Michael D. Jain	17
16	Patient-Reported Toxicities in Axicabtagene Ciloleucel Recipients: 1-Year Follow-up 2021 ·Transplantation and Cellular Therapy ·Anna Barata, Aasha I. Hoogland, Kelly A. Hyland, Anuhya Kommalapati, (unknown), (unknown), Margaret Booth‐Jones, Michael D. Jain, Frederick L. Locke, Heather Jim	1
17	Transverse myelitis after anti‐CD19 directed CAR T cell therapy for relapsed large B cell lymphoma 2021 ·SHILAP Revista de lepidopterología ·(unknown), Sepideh Mokhtari, Jeffrey A. Silverman, Kayla Reid, Rawan Faramand, Marco L. Davila, Norman Franke, Frederick L. Locke, Michael D. Jain, Daniel Wong, John Kuruvilla	10
18	Abstract 9828: Active Surveillance of Cardiotoxicity with Cardiac Biomarkers During Chimeric Antigen Receptor T-Cell Therapy 2021 ·Circulation ·Dae Hyun Lee, Sanjay Chandrasekhar, Michael D. Jain, Julio C. Chávez, Bijal Shah, Aleksandr Lazaryan, Farhad Khimani, Taiga Nishihori, Christina A. Bachmeier, Michael G. Fradley, Daniel Jeong, Frederick L. Locke, Guilherme José Pimentel Lopes de Oliveira, Mohammed Alomar	2
19	Factors Affecting Lymphocyte Collection Efficiency and Manufactured Product Specification during Leukapheresis for Diffuse Large B Cell Lymphoma Patients Treated with Commercial Tisagenlecleucel 2020 ·Blood ·Ariel Perez Perez, Christina A. Bachmeier, (unknown), (unknown), Aleksandr Lazaryan, Julio C. Chávez, Claudio Anasetti, Bijal Shah, Farhad Khimani, Taiga Nishihori, Marco L. Davila, Frederick L. Locke, Michael D. Jain, Hien Liu	3
20	Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US) 2019 ·Blood ·Marcelo C. Pasquini, Frederick L. Locke, Alex F. Herrera, Tanya Siddiqi, Armin Ghobadi, Krishna V. Komanduri, Zhen‐Huan Hu, Hua Dong, Peiman Hematti, Sarah Nikiforow, Patricia Steinert, Anna Purdum, Mary M. Horowitz, (unknown), Jun Kawashima, Caron A. Jacobson	72

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact